Fulvestrant (Fulvestrant) Patent Expiration, LOE Window & CMS Spending

Fulvestrant (Fulvestrant) by Fresenius Kabi: FDA Orange Book LOE 2034-05-17, 21 AB generics, $9.5M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorFresenius Kabi
FDA Application & PathwayN210326 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2034-05-17
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors21
2024 CMS Total Public Spend$9.5M
2024 Medicare Part D Spend$4.8M
2024 Medicaid Spend$4.7M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Fresenius / Fresenius Kabi across sibling Meru public-data platforms.